Detection and molecular staging of bladder cancer using real-time RT-PCR for gelatinases (MMP-2, MMP-9) and TIMP-2 in peripheral blood;Detección y estadificación molecular del cáncer vesical mediante RT-PCR a tiempo real para gelatinasas (MMP-2, MMP-9) y TIMP-2 en sangre periférica

Actas Urologicas Espanolas

Volumn 35, Issue 3, 2011, Pages 127-136

  Angulo, J C ^a   Ferruelo, A ^a   Rodriguez Barbero J M ^a   Nunez C ^a   De Fata, F R ^a   Gonzalez J ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Bladder neoplasia; MMP 2; MMP 9; Molecular staging; RT PCR; TIMP 2

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; BLADDER TUMOR; BLOOD; CANCER STAGING; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-2; URINARY BLADDER NEOPLASMS;

EID: 79952572880     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2010.10.006     Document Type: Article

References (30)

1. Angulo JC, López JI, Flores N, Toledo JD. The value of tumor spread, grading and growth pattern as morphologic predictive parameters in bladder carcinoma. A revision of 1987 TNM Classification J Cancer Res Clin Oncol. 1993;119:578-93.
2. Margulies IM, Hoyhtya M, Evans C, Stracke ML, Liotta LA, Stetler-Stevenson WG. Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomarkers Prev. 1992;1:467-74.
3. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 1993;53:5365-9. (Pubitemid 23342150)
4. Gohji K, Fujimoto N, Fujii A, Komiyama T, Okawa J, Nakajima M. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res. 1996;56:3196-8. (Pubitemid 26242960)
5. Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res. 1996;56:1654-9. (Pubitemid 26104031)
6. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998;58:1395-9.
7. Bianco Jr FJ, Gervasi DC, Tiguert R, Grignon DJ, Pontes JE, Crissman JD, et al. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin Cancer Res. 1998;4:3011-6. (Pubitemid 29001475)
8. Gohji K, Fujimoto N, Ohkawa J, Fujii A, Nakajima M. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer. 1998;77:650-5. (Pubitemid 28059475)
9. Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer. 1998;82:1359-66. (Pubitemid 28155399)
10. Hamasaki T, Hattori T, Kimura G, Nakazawa N. Tumor progression and expression of matrix metalloproteinase-2 (MMP-2) mRNA by human urinary bladder cancer cells. Urol Res. 1998;26:371-6. (Pubitemid 28566312)
11. Furukawa A, Tsuji M, Nishitani M, Kanda K, Inoue Y, Kanayama H, et al. Role of the matrix metalloproteinase and tissue inhibitor of metalloproteinase families in non-invasive and invasive tumors transplanted in mice with severe combined immunodeficiency. Urology. 1998;51:849-53. (Pubitemid 28261946)
12. Ozdemir E, Kakehi Y, Okuno H, Yoshida O. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J Urol. 1999;161:1359-63. (Pubitemid 29426157)
13. Kanda K, Takahasi M, Murakami Y, Kanayama H, Kagawa S. The role of the activated form of matrix-metalloproteinase-2 in urothelial cancer. Br J Urol Int. 2000;86:553-7.
14. Monier F, Mollier S, Guillot M, Rambeaud JJ, Morel F, Zaoui P. Urinary release of 72 and 92 kDa Gelatinases, TIMP-2. N-GAL and conventional prognostic factors in urothelial carcinomas Eur Urol. 2002;42:356-63.
15. Guan K, Ye H, Yan Z, Wang Y, Hou S. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology. 2003;61:719-23. (Pubitemid 36384961)
16. Eissa S, Labib RA, Mourad S, Kamel K, El-Ahmady O. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer. Eur Urol. 2003;44:687-94. (Pubitemid 37542927)
17. Gakiopoulou H, Nakopoulou L, Siatelis A, Mavrommatis I, Panayotopoulou EG, Tsirmpa I, et al. Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clinical Cancer Res. 2003;9:5573-81. (Pubitemid 37499477)
18. Durkan GC, Nutt JE, Marsh C, Rajjayabun PH, Robinson MC, Neal DE, et al. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer. Clin Cancer Res. 2003;9:2576-82. (Pubitemid 36842099)
19. Vasala K, Pääkkö P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology. 2003;62:952-7. (Pubitemid 37421256)
20. Sumi T, Yoshida H, Hyun Y, Yasui T, Matsumoto Y, Hattori K, et al. Expression of matrix metalloproteinases in human transitional cell carcinoma of the urinary bladder. Oncology Reports. 2003;10:345-9.
21. Chaffer CL, Dopheide B, McCulloch DR, Lee AB, Moseley JM, Thompson EW, et al. Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder. Clin Exper Metastases. 2005;22:115-25. (Pubitemid 41185849)
22. Vasala K, Turpeennniemi-Hujanen T. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer. Clin Biochem. 2007;40:640-4. (Pubitemid 46829065)
23. Vasala K, Kuvaja P, Turpeenniemi-Hujanen T. Low circulating levels od proMMP-2 are associated with adverse prognosis in bladder cancer. Tumour Biol. 2008;29:279-86.
24. Fernández CA, Wszolek MF, Loughlin KR, Libertino JA, Summerhayes IC, Shuber AP. A novel approach to using matrix metalloproteinases for bladder cancer. J Urol. 2009;182:2188-94.
25. Grimm MO, Modlich O, Brosius U, Struse K, Bojar H, Vogeli TA. Expression and progression pattern of transitional cell carcinoma of the bladder. J Urol. 2000;4:557.
26. Szarvas T, Becker M, Dorp FV, Gethmann C, Tötsch M, Bánkfalvi A, Schmid KW, et al. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci. 2010;101:1300-8.
27. Rodríguez Faba O, Fernández Gómez JM, Palou Redorta J, Escaf Barmadah S, Vizoso F, Villavicencia Mavrich H. Significance of collagenase 3 (matrix metalloproteinase 13) in invasive bladder cancer: correlation with pathological parameters. Urol Int. 2007;78:140-4. (Pubitemid 46239134)
28. Naruo S, Kanayama H, Takigawa H, Kagawa S, Yamashita K, Hayakawa T. Serum levels of a tissue inhibitor of metalloproteinase-1 (TIMP-1) in bladder cancer patients. Int J Urol. 1994;1:228-31. (Pubitemid 2156451)
29. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med. 2004;42:121-31. (Pubitemid 38401437)
30. Masson V, de la Ballina LR, Munaut C, Wielockx B, Jost M, Maillard C, et al. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J. 2005;19:234-6. (Pubitemid 40189266)